Latest Liquidity News

Regal Investment Fund reported a remarkable half-year performance with a 201% increase in operating profit and a 12 cents per unit distribution declared for December 2025. The Fund's strategic buy-back program and strong net asset growth underscore its robust position.

SciDev Limited posted a $2.14 million loss for the half-year ending December 2025, impacted by restructuring costs and a failed acquisition. Despite a 4% revenue dip, the company secured a major $19.5 million contract and maintains a strong balance sheet.

Tabcorp Holdings reported a modest 1% revenue increase for the half year ending December 2025, while adjusted net profit after tax jumped 61.5%, prompting a 50% rise in the interim dividend.

Embark Early Education Limited delivered a robust 2025 financial performance, marked by significant revenue and EBITDA growth, while setting sights on expanding through a strategic takeover bid for Mayfield Childcare Limited.

Wisr Limited reports robust half-year growth with a 23% increase in its loan book and a 14% rise in revenue, setting the stage for expected cash profitability in the second half of FY26.

Amplitude Energy has delivered a standout half-year performance with record gas production and a 246% jump in profit, while advancing key projects and strengthening its balance sheet.

Big River Industries has posted a $1.4 million profit for the half-year ending December 2025, reversing a substantial loss from the previous year, while completing a strategic acquisition in Perth.

SiteMinder Limited reported a robust 25.5% revenue increase to $131.1 million in H1FY26, alongside a significant reduction in statutory loss to $4.78 million, driven by its Smart Platform strategy and disciplined cost management.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

Bapcor Limited has postponed its half-year financial results release to no later than 27 February 2026 and is seeking an extension of its trading suspension, hinting at a potential capital raising.

Metro has announced a significant share consolidation, reducing its total shares on issue from nearly 984 million to approximately 24.6 million. The move aims to streamline the capital structure ahead of trading resumption in early March.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.